Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD) Research Samples
19 Results
1 - 19 of 19 total samples.
Advanced Data View:
1 - 19 of 19 total samples.
Buy | Product ID | Sample | Origin | Matrix | Vial (ml) | Quantity | Price | Age | Gender | Ethnicity | Storage Temp | Sample Date | Test 1 | Test 1 Result | Test 1 Detail | Test 2 | Test 2 Result | Test 3 | Test 3 Result | Product Details | Price | Buy | Elastography Result | Comorbidities | Ultrasound Result | Smoking Status | Alcohol Consumption | HIV-I/II, Hepatitis B, Hepatitis C Test Results | CT / MRI results |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| BF19871170 | Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD) | Ukraine | Serum | 1.00 | 14.00 | $400.00 | 61 Y | F | White | <-70C | 02-Oct-25 | Diagnosis | Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD) | 2-Oct-2025 | Height | 155 cm | Weight | 61 kg | $400.00 | Mean liver stiffness: 6.4 kPa (F1 by METAVIR) 2-Oct-2025 | Hypertension 2019 | Signs of steatohepatosis | Never used | Never used | Negative | ||||
| BF19871172 | Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD) | Ukraine | Serum | 1.00 | 14.00 | $400.00 | 69 Y | F | White | <-70C | 01-Oct-25 | Diagnosis | Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD) | 1-Oct-2025 | Height | 159 cm | Weight | 67 kg | $400.00 | Mean liver stiffness: 6.6 kPa (F1 by METAVIR) 1-Oct-2025 | Hypertension; Heart failure 2007; 2010 | Findings of steatohepatitis and chronic calculous cholecystitis in remission. Cholelithiasis | Never used | Never used | Negative | ||||
| BF19871190 | Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD) | Ukraine | Serum | 1.00 | 13.00 | $400.00 | 72 Y | F | White | <-70C | 17-Oct-25 | Diagnosis | Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD) | 2021 | Height | 158 cm | Weight | 75 kg | $400.00 | Mean liver stiffness: 7.5 kPa (F 2 by METAVIR) 17-Oct-2025 | Hypertension 2007 | Never used | Never used | Negative | |||||
| BF19871192 | Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD) | Ukraine | Serum | 1.00 | 13.00 | $400.00 | 58 Y | F | White | <-70C | 17-Oct-25 | Diagnosis | Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD) | 17-Oct-2025 | Height | 162 cm | Weight | 88 kg | $400.00 | Mean liver stiffness: 8.2 kPa (F3 by METAVIR) 17-Oct-2025 | Ischemic heart disease; Hypertension; Diabetes mellitus type 2; Obesity class I 2019; 2021; 2022; 2019 | Never used | Never used | Negative | |||||
| BF19871195 | Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD) | Ukraine | Serum | 1.00 | 14.00 | $400.00 | 67 Y | F | White | <-70C | 22-Oct-25 | Diagnosis | Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD) | 22-Oct-2025 | Height | 153 cm | Weight | 69 kg | $400.00 | Mean liver stiffness: 6.3 kPa (F1 by METAVIR) 22-Oct-2025 | Chronic obstructive pulmonary disease; Diabetes mellitus type 2 2003; 2006 | Never used | Never used | Negative | |||||
| BF19871196 | Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD) | Ukraine | Serum | 1.00 | 14.00 | $400.00 | 74 Y | F | White | <-70C | 16-Oct-25 | Diagnosis | Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD) | 10-Oct-2025 | Height | 169 cm | Weight | 90 kg | $400.00 | Mean liver stiffness: 6.2 kPa (F1 by METAVIR) 10-Oct-2025 | Ischemic heart disease; Hypertension 2002; 2006 | Never used | Never used | Negative | |||||
| BF19871228 | Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD) | Ukraine | Serum | 1.00 | 1.00 | $500.00 | 54 Y | M | White | <-70C | 18-Feb-25 | Diagnosis | Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD) | 2012 | Height | 176 cm | Weight | 74 kg. | $500.00 | Oblique vertical size of the right lobe 178 mm, left lobe 76 mm. The structure is changed, fatty degeneration 70%. K3 is 297 dB/m. Steatosis S3. 27-Jan-25 | N/A | Never used | Never used | Negative | |||||
| BF19871251 | Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD) | Ukraine | Serum | 1.00 | 1.00 | $500.00 | 34 Y | M | White | <-70C | 12-Feb-25 | Diagnosis | Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD) | 2022 | Height | 178 cm | Weight | 76 kg. | $500.00 | Oblique vertical size of the right lobe 162 mm, left lobe 70 mm. The structure is changed, fatty degeneration 35%. K3 is 258 dB/m. Steatosis S2. 22-Jan-25 | N/A | Never used | Never used | Negative | |||||
| BF19871280 | Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD) | Ukraine | Serum | 1.00 | 1.00 | $500.00 | 53 Y | F | White | <-70C | 18-Feb-25 | Diagnosis | Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD) | 2022 | Height | 167 cm | Weight | 72 kg. | $500.00 | The average value of the elasticity of the parenchyma of the liver is 6.2 kPa. On the METAVIR scale - F1. 18-Feb-25 | N/A | Never used | Never used | Negative | |||||
| BF19871283 | Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD) | Ukraine | Serum | 1.00 | 1.00 | $500.00 | 40 Y | M | White | <-70C | 18-Feb-25 | Diagnosis | Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD) | 2018 | Height | 178 cm | Weight | 75 kg. | $500.00 | Oblique vertical size of the right lobe 168 mm, left lobe 80 mm. The structure is changed, fatty degeneration 40%. K3 is 258 dB/m. Steatosis S2. 30-Jan-25 | N/A | Never used | Never used | Negative | |||||
| BF19871288 | Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD) | Ukraine | Serum | 1.00 | 1.00 | $500.00 | 48 Y | M | White | <-70C | 17-Apr-25 | Diagnosis | Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD) | 16-Apr-25 | Height | 187 cm | Weight | 75 kg. | $500.00 | Elastometry results: Young's median 6.5 kPa, 1.52 m/s (IQR <30%) corresponding to F1-F2 for METAVIR scale. Moderate steatosis. 16-Apr-25 | N/A | Never used | Never used | Negative | The liver is slightly enlarged. The oblique vertical dimension of the right lobe of the liver is 162 mm, the thickness of the left lobe is 78 mm, contours are smooth, the boundaries are clear. The structure is heterogeneous due to perportal fibrosis | ||||
| BF19871335 | Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD) | Ukraine | Serum | 1.00 | 13.00 | $400.00 | 55 Y | F | White | <-70C | 29-Oct-25 | Diagnosis | Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD) | 2022 | Height | 165 cm | Weight | 88 kg | $400.00 | Mean liver stiffness: 4.84 kPa (F0-F1 by METAVIR) 20-Oct-2025 | Obesity class I 2014 | Never used | Current Use (1/day, 20 years) | Negative | |||||
| BF19871336 | Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD) | Ukraine | Serum | 1.00 | 12.00 | $400.00 | 55 Y | M | White | <-70C | 30-Oct-25 | Diagnosis | Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD) | 6-Oct-2025 | Height | 182 cm | Weight | 117 kg | $400.00 | Mean liver stiffness: 4.67 kPa (F0-F1 by METAVIR) 6-Oct-2025 | Chronic pancreatitis; Obesity class II 2011; 2011 | Previous Cigarette Use (15/day, 7 years, Quit in 2011) | Previous Use (2/day, 7 years, Quit in 2011) | Negative | |||||
| BF19871337 | Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD) | Ukraine | Serum | 1.00 | 14.00 | $400.00 | 55 Y | F | White | <-70C | 28-Oct-25 | Diagnosis | Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD) | 2015 | Height | 163 cm | Weight | 92 kg | $400.00 | Mean liver stiffness: 3.24 kPa (F0-F1 by METAVIR) 27-Oct-2025 | Diabetes mellitus type 2; Obesity class I 2008; 2005 | Never used | Previous Use (1/day, 3 years, Quit in 2008) | Negative | |||||
| BF19871338 | Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD) | Ukraine | Serum | 1.00 | 13.00 | $400.00 | 35 Y | M | White | <-70C | 29-Oct-25 | Diagnosis | Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD) | 7-Jan-2025 | Height | 185 cm | Weight | 122 kg | $400.00 | Mean liver stiffness: 3.64 kPa (F0-F1 by METAVIR) 21-Oct-2025 | Obesity class II 2022 | Previous Cigarette Use (15/day, 2 years, Quit in 2022) | Previous Use (2/day, 2 years, Quit in 2022) | Negative | |||||
| BF19871339 | Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD) | Ukraine | Serum | 1.00 | 13.00 | $400.00 | 45 Y | M | White | <-70C | 28-Oct-25 | Diagnosis | Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD) | 25-Oct-2025 | Height | 176 cm | Weight | 125 kg | $400.00 | Mean liver stiffness: 4.39 kPa (F0-F1 by METAVIR) 25-Oct-2025 | Obesity class III 2010 | Never used | Never used | Negative | |||||
| BF19871340 | Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD) | Ukraine | Serum | 1.00 | 14.00 | $400.00 | 42 Y | M | White | <-70C | 28-Oct-25 | Diagnosis | Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD) | 2021 | Height | 190 cm | Weight | 115 kg | $400.00 | Mean liver stiffness: 4.87 kPa (F0-F1 by METAVIR) 14-Oct-2025 | Diabetes mellitus type 2; Obesity class I 2010; 2007 | Never used | Never used | Negative | |||||
| BF19871347 | Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD) | Ukraine | Serum | 1.00 | 14.00 | $400.00 | 52 Y | F | White | <-70C | 29-Oct-25 | Diagnosis | Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD) | 3-Oct-2025 | Height | 178 cm | Weight | 119 kg | $400.00 | Mean liver stiffness: 4.34 kPa (F0-F1 by METAVIR) 3-Oct-2025 | Diabetes mellitus type 2; Obesity class II 2020; 2010 | Never used | Never used | Negative | |||||
| BF19871453 | Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD) | Ukraine | Serum | 1.00 | 12.00 | $400.00 | 49 Y | M | White | <-70C | 17-Feb-26 | Diagnosis | Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD) | 2-Jan-26 | Height | 172 cm | Weight | 94 kg | $400.00 | Mean liver stiffness: 8.2 kPa (F3 by METAVIR) 17-Feb-26 | Hypertension; Obesity class I 2020; 2018 | Never used | Never used | Negative |